T1	Participants 270 316	patients with CKD, including dialysis patients
T2	Participants 495 512	patients with CKD
T3	Participants 833 892	2353 SHARP participants who had functioning vascular access
T4	Participants 1378 1532	AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) trial cohort
